KINIKSA PHARMACEUTICALS LTD's ticker is KNSA and the CUSIP is G5269C101. A total of 133 filers reported holding KINIKSA PHARMACEUTICALS LTD in Q1 2023. The put-call ratio across all filers is 0.58 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $611 | +16.4% | 35,200 | -5.6% | 0.00% | +50.0% |
| Q2 2023 | $525 | -66.5% | 37,300 | -74.4% | 0.00% | 0.0% |
| Q1 2023 | $1,566 | +174.7% | 145,800 | +282.7% | 0.00% | -33.3% |
| Q4 2022 | $570 | -99.8% | 38,100 | +186.5% | 0.00% | +200.0% |
| Q4 2020 | $235,000 | -51.7% | 13,300 | -58.2% | 0.00% | -50.0% |
| Q3 2020 | $487,000 | -18.6% | 31,800 | +35.3% | 0.00% | -33.3% |
| Q2 2020 | $598,000 | +43.4% | 23,500 | -13.0% | 0.00% | +50.0% |
| Q1 2020 | $417,000 | +179.9% | 27,000 | +100.0% | 0.00% | +100.0% |
| Q4 2019 | $149,000 | -34.6% | 13,500 | -50.0% | 0.00% | 0.0% |
| Q3 2019 | $228,000 | +25.3% | 27,000 | +100.0% | 0.00% | 0.0% |
| Q2 2019 | $182,000 | +106.8% | 13,500 | +175.5% | 0.00% | – |
| Q1 2019 | $88,000 | -35.8% | 4,900 | 0.0% | 0.00% | -100.0% |
| Q4 2018 | $137,000 | +185.4% | 4,900 | +157.9% | 0.00% | – |
| Q3 2018 | $48,000 | – | 1,900 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Spearhead Capital Advisors, LLC | 202,580 | $2,601,000 | 2.82% |
| Lion Point Capital, LP | 480,000 | $5,140,000 | 1.13% |
| HHLR ADVISORS, LTD. | 2,920,023 | $37,493,000 | 0.99% |
| TANG CAPITAL MANAGEMENT LLC | 600,000 | $7,704,000 | 0.94% |
| Rubric Capital Management LP | 1,446,107 | $18,568,000 | 0.94% |
| AlphaCentric Advisors LLC | 43,000 | $552,000 | 0.57% |
| RICE HALL JAMES & ASSOCIATES, LLC | 749,933 | $9,629,000 | 0.56% |
| Parkman Healthcare Partners LLC | 126,192 | $1,620,000 | 0.46% |
| Birchview Capital, LP | 30,000 | $385,000 | 0.27% |
| Baker Brothers Advisors | 2,799,577 | $35,947,000 | 0.24% |